MammaPrint genetic testing reduces chemotherapy overtreatment in breast cancer patients

Share it with your friends Like

Thanks! Share it with your friends!

Close

Martine Piccart, MD, PhD & Head of the Medicine Department at the Jules Bordet Institute and Co-Founder of the Breast International Group (BIG) discusses primary analysis of the EORTC 10041/BIG 3-04 MINDACT study: A prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes at the American Association of Cancer Research Annual Meeting 2016 (AACR16).

MDLinx Conference Coverage – American Association of Cancer Research Annual Meeting 2016: http://www.mdlinx.com/oncology/conference-interview/american-association-of-cancer-research-annual-meeting-2016/231097

MDLinx: http://www.mdlinx.com/
Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/
M3 USA: http://usa.m3.com/

Follow MDLinx:
Facebook – https://www.facebook.com/MDLinx
Twitter – https://twitter.com/MDLinx
Google+ – https://plus.google.com/+Mdlinx/

Comments

Write a comment